Double Trouble: Dual Antiplatelet Therapy Duration Dilemma in Chronic Kidney Disease Patients With High Bleeding Risk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Double Trouble: Dual Antiplatelet Therapy Duration Dilemma in Chronic Kidney Disease Patients With High Bleeding Risk

Published:2024-09 Issue: Volume:226 Page:137-139
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Paul Timir K.

Publisher

Elsevier BV

Reference16 articles.

1. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: an analysis from the PRODIGY trial;Gargiulo;Catheter Cardiovasc Interv,2017

2. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis;Palmer;Ann Intern Med,2012

3. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

4. Dual antiplatelet therapy after PCI in patients at high bleeding risk;Valgimigli;N Engl J Med,2021

5. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI;Valgimigli;J Am Coll Cardiol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3